Microarrays and microneedle arrays for delivery of peptides, proteins, vaccines and other applications
ABSTRACT Introduction: Peptide and protein microarray and microneedle array technology provides direct information on protein function and potential drug targets in drug discovery and delivery. Because of this unique ability, these arrays are well suited for protein profiling, drug target identification/validation and studies of protein interaction, biochemical activity, immune responses, clinical prognosis and diagnosis and for gene, protein and drug delivery. Areas covered: The aim of this review is to describe and summarize past and recent developments of microarrays in their construction, characterization and production and applications of microneedles in drug delivery. The scope and limitations of various technologies in this respect are discussed. Expert opinion: This article offers a review of microarray/microneedle technologies and possible future directions in targeting and in the delivery of pharmacologically active compounds for unmet needs in biopharmaceutical research. A better understanding of the production and use of microarrays and microneedles for delivery of peptides, proteins and vaccines is needed.
- SourceAvailable from: Ming-Wei Wang
[Show abstract] [Hide abstract]
- "In addition to DNA microarrays, protein chips are also utilized in drug discovery (Chandrasekhar et al. 2013). The feasibility of using protein microarray in HTS was established at the beginning of this century (MacBeath and Schreiber 2000; Zhu et al. 2000). "
ABSTRACT: Drug discovery and development is vital to the well-being of mankind and sustainability of the pharmaceutical industry. Using chemical biology approaches to discover drug leads has become a widely accepted path partially because of the completion of the Human Genome Project. Chemical biology mainly solves biological problems through searching previously unknown targets for pharmacologically active small molecules or finding ligands for well-defined drug targets. It is a powerful tool to study how these small molecules interact with their respective targets, as well as their roles in signal transduction, molecular recognition and cell functions. There have been an increasing number of new therapeutic targets being identified and subsequently validated as a result of advances in functional genomics, which in turn led to the discovery of numerous active small molecules via a variety of high-throughput screening initiatives. In this review, we highlight some applications of chemical biology in the context of drug discovery.Archives of Pharmacal Research 08/2015; DOI:10.1007/s12272-015-0643-2 · 1.75 Impact Factor
[Show abstract] [Hide abstract]
- "Microneedle (MN) devices are composed of an array of micronsize needles. These systems are currently attracting great interest in transdermal drug delivery research (Chandrasekhar et al., 2013; Henry et al., 1998; Kim et al., 2012; Tuan-Mahmood et al., 2013). MN has the ability to pierce the outermost layer of the skin, the stratum corneum (SC) and create micro-conduits that can deliver drugs to the deeper layers of the skin from where they can be absorbed directly into the systemic circulation (Prausnitz, 2004). "
ABSTRACT: Figure optionsDownload full-size imageDownload high-quality image (403 K)Download as PowerPoint slideInternational Journal of Pharmaceutics 01/2014; · 3.65 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Aim: This study aimed to investigate transdermal delivery of proteins using combination of microporation and iontophoresis (ITP). Materials & methods & results: Delivery of model protein, Alexa Fluor 555 bovine serum albumin conjugate (AF-BSA) using ITP alone, microneedle (MN) alone, and ITP plus MN combination was assessed using confocal microscopy. Compared to MN alone, combination of MN plus ITP significantly increased skin's penetration depth of AF-BSA (300 vs 110 μm) and achieved lateral distribution of the model protein. Average fluorescence intensity quantified around each microchannel was 23.7-fold (8.2-fold, in vivo) higher for combination treatment compared with MN alone, in vitro. After 1 h in vitro permeation study, the unlabeled BSA amount delivered across skin was found to be 0, 1.4, 0.63 and 14 μg by passive, MN alone, ITP alone and ITP plus MN combination delivery, respectively.Therapeutic delivery 05/2014; 5(5):525-36. DOI:10.4155/tde.14.19